-47.8%
IREN vs GSK
+40.7%
-88.4%
-95.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -18.0% | -0.1% | -17.8% | -18.0% |
| 7D | -34.9% | -5.3% | -29.6% | -36.2% |
| 30D | -57.5% | -3.7% | -53.9% | -57.9% |
| 3M | -72.3% | -7.3% | -65.0% | -72.6% |
| 6M | -77.6% | -4.2% | -73.3% | -77.5% |
| YTD | -68.7% | +0.9% | -69.6% | -68.0% |
| 1Y | -72.8% | +7.3% | -80.1% | -71.8% |
| 3Y | +302.0% | +52.7% | +249.3% | +343.2% |
| All | -47.8% | +40.7% | -88.4% | -41.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling